The Biggest Biotech Story Of 2021?

On October 10, 1962, JFK signed into law a little-known act that helped put a massive $1.25 trillion industry on the map.

This is a sponsored article from SafeHaven.com

And today, the trillion-dollar pharmaceutical industry is being pushed to make a shift.

I’m talking about a new way to create safe, proven treatments while saving companies significant amounts of money…

Treatments that could help ease common ailments that plague millions of folks each year like chronic pain, inflammation, migraines, and more.

It could have tremendous implications for the future of the biotech market.

That’s because the 1962 Kefauver Harris Amendment helped make sure the medications we take are both safe and effective…

But that often came with long, arduous review processes that left desperate people waiting years for relief. 

In 2020, however, we’ve seen a massive shift take place in the biotech industry thanks to the fast-tracked COVID vaccine…

Proving that with today’s technology, it’s finally possible to cut through the red tape in the process…

Delivering the potential to produce treatments and vaccines that are both safe and effective at record speeds.

And now, the next possible breakthrough in health sciences is in the perfect position to capitalize on that in 2021 and the little known company at the forefront is called Juva Life (CSE: JUVA; OTC: JUVAF)

While some may still be skeptical of its benefits, consider this…

Many of the companies in this market are seeing incredible gains this year.

Harborside, Inc., a San Francisco-based dispensary operator, saw shares soar 423% in just 9 months.

Indus Holdings, another manufacturer and distributor in the Bay Area, launched for extraordinary 528% gains in 2020.

But some investors are keeping their eyes on another young company near San Francisco that has big plans in store.

In December, their shares were up an impressive 44% in just three weeks.

But with a target to do things differently, they have even greater plans in the months to come.

Juva Life (CSE: JUVA; OTC: JUVAF) aims to have a large database for evidence-based cannabis treatments…

And they’ll soon have the facilities to take that valuable data proving what works best and for who…

And turn it into an asset that could potentially make them an instant acquisition target.

Here are 3 key reasons why you should be watching Juva Life.

A New Path for Safe, Effective Treatments

The start of this massive boom began in California, when they legalized medical marijuana with overwhelming support in 1996.

Since then, dozens of other states and entire nations have jumped onboard…

And the global cannabis industry is expected to reach an incredible $57 billion by 2025.

That’s helping to ease the suffering of countless people around the world struggling with conditions from migraines and chronic pain to cancer.

In fact, in a breakthrough study, 92% of patients said that medical marijuana was helpful in alleviating their symptoms.

But in this booming industry, there’s been one huge problem.

With federal laws still classifying medical marijuana as a Schedule I drug, it’s stifled their ability to conduct the studies proving the incredible effects that individuals have been reporting for years.

That’s why Juva Life has aimed to create a very detailed database, unlocking a whole new world of opportunities.

It’s expected to be the first major database compiling data for proven, effective treatments in this long-overlooked area.

So rather than going through a process that can cost up to $2.6 billion to develop a new treatment through the FDA…

And can take up to a decade of time…

Juva Life will use an IRB-approved process that could lead to effective treatments with just a fraction of the cost and time.

But the most exciting part is that after they’ve compiled the data…

Juva Life plans to use artificial intelligence (AI), proprietary software, and their team’s collective decades of experience to create proprietary versions of the most effective, proven treatments.

That means after proving these treatments to be safe and effective…

They could license versions of these treatments themselves, potentially driving massive revenue while providing help to those who need it.

It’s a change that could be noticed through the biotech industry.

And within the field of health sciences, it’s creating an opportunity that could see Juva Life at the center of it all.

But for the team leading the charge, this isn’t their first go-around in this exciting new field.

The Track Record to Deliver a Biotech Process

With the process that Juva Life (CSE: JUVA; OTC: JUVAF) could soon unveil to the health sciences industry, they’ve got big plans.

But unlike others starting out in the cannabis industry…

Their team has both the credentials and the hard-earned experience matched by few other companies.

Their CEO, Doug Chloupek, is a pioneer in the industry in California and boasts more than a decade of experience running cannabis companies there.

He was the first to receive a permit to conduct research and manufacturing in the state back in 2016…

Helping set the foundation of what’s projected to become a $57 billion industry in the state by 2025.

And he’ll be working with world-class doctors and scientists like Dr. Guy Miller.

Dr. Miller is a double-PhD anesthesiologist and ER physician, and his list of credentials is enormous.

On top of being an advisor to Johnson & Johnson for nearly a decade, he’s also a Adjunct facility memberat Johns Hopkins and CEO of Wheel Biology. 

After working directly with C-level executives for some of the big biotech companies, he’s been planting the seed for what Juva Life is creating.

And he’s joined by Dr. Sanjeev Gangwar as VP of Chemistry, the former director of Oncology at Bristol-Myers Squibb, the $138 billion biotech juggernaut.

He’s written 41 patents, 30 global lectures and 40 publications, proving he’s no stranger to putting supporting data behind the treatments that can change lives.

With Juva Life’s team of accomplished entrepreneurs, physicians, and scientists, they’ve assembled a team of folks that aims to answer the multi-billion-dollar questions everyone is asking…

Does cannabis work? Who does it work for? And how does it work? 

Plus, with the potential to build a patent portfolio of products themselves…

This dream team could be just what the industry needed to take it to the next level…

Providing what could become an incredible surge in its business if they prove successful.

Already Driving Revenue – And the Pace is Picking Up

With their new database set to open new opportunities, Juva Life (CSE: JUVA; OTC: JUVAF) has also been busy driving revenue through the other arm of their business.

While it usually costs over $2 billion to develop new treatments the old way through the FDA…

They are aiming to cut years, billions of dollars, and lots of risk out of the process because of the IRB-approved processes they can conduct their research through.

And they plan to fund this database in part through their other verticals, which are already bringing in revenue with paying customers.

Juva Life has pinpointed what they see as strategic holes in the market all around the San Francisco area, including retail and delivery services.

And they opened operations in Redwood City and Stockton in 2020

They’ve been delivering the best, most trusted products to the area for several months already…

But soon, they plan on creating and distributing their own in-house brands.

They’ve already received local approval to open their production facility shortly, and they’re expected to be producing their own products within 6-8 months.

The revenue Juva Life has already been able to drive from a secondary asset is important.

Particularly during a year when many businesses have been shuttered due to the pandemic and government shutdowns.

But with the major moves they have in store, the timeline for this small company is moving quickly.

In the coming weeks, they hope to have the new database off the ground, then later enrolling patients in the studies that could modernize parts of the biotech industry.

At the same time, they’re expected to begin cultivating their own products which could soon become the most trusted, evidence-based brand on the markets.

And with Juva Life (CSE: JUVA; OTC: JUVAF) pioneering a model that could save the big players piles of cash in the drug development process, if it works as planned this could make draw major attention as a potential acquisition target in the near future.

It’s an opportunity that could disrupt a part of the entire industry.

The Last Word

  • The trillion-dollar biotech industry is sitting on a potential medical application that The Guardian says is “attracting big players.”
  • Juva Life’s innovative plan, if successful, could help create safe, effective treatments at record speed and at a fraction of the price compared to standard Big Pharma practices.
  • Their team is led by a CEO with over a decade of experience in the industry, and he’s recruited some of the top doctors and scientists in the game.
  • They’ve already started driving revenue through retail and delivery operations.
  • Over the next several months, they plan to have their one-of-a-kind database up and running, with patients recruited to the studies that could become valuable.
  • Their database could make them a prime acquisition target from billion-dollar giants in the health sciences industry.

By. Zara Newman

DISCLAIMERS
PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities.

TERMS OF USE. By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://safehaven.com/terms-and-conditions If you do not agree to the Terms of Use https://safehaven.com/terms-and-conditions, please contact SafeHaven.com to discontinue receiving future communications.